Tarsus Pharmaceuticals (NASDAQ: TARS)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-03 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-05-27 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Tarsus Pharmaceuticals (NASDAQ: TARS) through any online brokerage.
Other companies in Tarsus Pharmaceuticals’s space includes: GH Research (NASDAQ:GHRS), Aerie Pharmaceuticals (NASDAQ:AERI), Verona Pharma (NASDAQ:VRNA), ANI Pharmaceuticals (NASDAQ:ANIP) and Provention Bio (NASDAQ:PRVB).
The latest price target for Tarsus Pharmaceuticals (NASDAQ: TARS) was reported by HC Wainwright & Co. on Tuesday, December 21, 2021. The analyst firm set a price target for 40.00 expecting TARS to rise to within 12 months (a possible 204.65% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Tarsus Pharmaceuticals (NASDAQ: TARS) is $13.13 last updated May 13, 2022, 8:00 PM UTC.
There are no upcoming dividends for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals’s Q2 earnings are confirmed for Wednesday, August 3, 2022.
There is no upcoming split for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.